<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34517053</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>195</Volume><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species.</ArticleTitle><Pagination><StartPage>105177</StartPage><MedlinePgn>105177</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2021.105177</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(21)00167-4</ELocationID><Abstract><AbstractText>Vapendavir is a rhino/enterovirus inhibitor that targets a hydrophobic pocket in the viral capsid preventing the virus from entering the cell. We set out to study and compare the molecular mechanisms of resistance to vapendavir among clinically relevant Picornavirus species. To this end in vitro resistance selection of drug-resistant isolates was applied in rhinovirus 2 and 14, enterovirus-D68 and Poliovirus 1 Sabin. Mutations in the drug-binding pocket in VP1 (C199R/Y in hRV14; I194F in PV1; M252L and A156T in EV-D68), typical for this class of compounds, were identified. Interestingly, we also observed mutations located outside the pocket (K167E in EV-D68 and G149C in hRV2) that contribute to the resistant phenotype. Remarkably, the G149C substitution rendered the replication of human rhinovirus 2 dependent on the presence of vapendavir. Our data suggest that the binding of vapendavir to the capsid of the G149C isolate may be required to stabilize the viral particle and to allow efficient dissemination of the virus. We observed the dependency of the G149C isolate on other compounds of this class, suggesting that this phenotype is common for capsid binders. In addition the VP1 region containing the G149C substitution has not been associated with antiviral resistance before. Our results demonstrate that the phenotype and genotype of clinically relevant vapendavir-resistant picornavirus species is more complex than generally believed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanko</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froeyen</LastName><ForeName>Mathy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Rega Institute for Medical Research, Laboratory of Medicinal Chemistry, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delang</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirabelli</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium. Electronic address: johan.neyts@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010849" MajorTopicYN="N">Picornaviridae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">Capsid binders</Keyword><Keyword MajorTopicYN="N">Drug resistance</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>13</Day><Hour>20</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34517053</ArticleId><ArticleId IdType="pmc">PMC8593553</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2021.105177</ArticleId><ArticleId IdType="pii">S0166-3542(21)00167-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abzug M.J., Cloud G., Bradley J., S&#xe1;nchez P.J., Romero J., Powell D., Lepow M., Mani C., Capparelli E.V., Blount S., Lakeman F., Whitley R.J., Kimberlin D.W. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr. Infect. Dis. J. 2003;22:335&#x2013;340. doi: 10.1097/00006454-200304000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-200304000-00009</ArticleId><ArticleId IdType="pubmed">12690273</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug M.J., Michaels M.G., Wald E., Jacobs R.F., Romero J.R., S&#xe1;nchez P.J., Wilson G., Krogstad P., Storch G.A., Lawrence R., Shelton M., Palmer A., Robinson J., Dennehy P., Sood S.K., Cloud G., Jester P., Acosta E.P., Whitley R., Kimberlin D., National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J. Pediatric Infect. Dis. Soc. 2015;5:piv015. doi: 10.1093/jpids/piv015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piv015</ArticleId><ArticleId IdType="pmc">PMC4765488</ArticleId><ArticleId IdType="pubmed">26407253</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliabadi N., Messacar K., Pastula D.M., Robinson C.C., Leshem E., Sejvar J.J., Nix W.A., Oberste M.S., Feikin D.R., Dominguez S.R. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg. Infect. Dis. 2016;22:1387&#x2013;1394. doi: 10.3201/eid2208.151949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2208.151949</ArticleId><ArticleId IdType="pmc">PMC4982171</ArticleId><ArticleId IdType="pubmed">27434186</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., Van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018 doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Benschop K.S.M., Wildenbeest J.G., Koen G., Minnaar R.P., van Hemert F.J., Westerhuis B.M., Pajkrt D., van den Broek P.J., Vossen A.C.T.M., Wolthers K.C. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J. Gen. Virol. 2015;96:571&#x2013;579. doi: 10.1099/vir.0.069773-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.069773-0</ArticleId><ArticleId IdType="pubmed">25395595</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun H., Kirchmair J., Williamson M.J., Makarov V.A., Riabova O.B., Glen R.C., Sauerbrei A., Schmidtke M. Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket. Antivir. Res. 2015;123:138&#x2013;145. doi: 10.1016/j.antiviral.2015.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.09.009</ArticleId><ArticleId IdType="pubmed">26391975</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett M.S., Hincks J.R., Benschop K., Duizer E., van der Avoort H., Rhoden E., Liu H., Oberste M.S., McKinlay M.A., Hartford M. Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J. Infect. Dis. 2016;215:jiw542. doi: 10.1093/infdis/jiw542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw542</ArticleId><ArticleId IdType="pmc">PMC5393058</ArticleId><ArticleId IdType="pubmed">27932608</ArticleId></ArticleIdList></Reference><Reference><Citation>Case D.A., Ben-Shalom I.Y., Brozell S.R., Cerutti D.S., Cheatham T.E., Cruzeiro V.W.D., III, Darden T.A., Duke R.E., Ghoreishi D., Gilson M.K., Gohlke H., Goetz A.W., Greene D., Harris R., Homeyer N., Izadi S., Kovalenko A., Kurtzman T., Lee T.S., LeGra S. 2018. AMBER 2018. D.M.Y. and P.A.K.</Citation></Reference><Reference><Citation>Delang L., Segura Guerrero N., Tas A., Qu&#xe9;rat G., Pastorino B., Froeyen M., Dallmeier K., Jochmans D., Herdewijn P., Bello F., Snijder E.J., de Lamballerie X., Martina B., Neyts J., van Hemert M.J., Leyssen P. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J. Antimicrob. Chemother. 2014;69:2770&#x2013;2784. doi: 10.1093/jac/dku209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku209</ArticleId><ArticleId IdType="pubmed">24951535</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana G.D., Salvador U.J., Zalay E.S., Johnson R.E., Collins J.C., Johnson D., Hinshaw W.B., Lorenz R.R., Thielking W.H., Pancic F. Antiviral activity of some &#x3b2;-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses. J. Med. Chem. 1977;20:750&#x2013;756. doi: 10.1021/jm00216a003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00216a003</ArticleId><ArticleId IdType="pubmed">195054</ArticleId></ArticleIdList></Reference><Reference><Citation>Feil S.C., Hamilton S., Krippner G.Y., Lin B., Luttick A., McConnell D.B., Nearn R., Parker M.W., Ryan J., Stanislawski P.C., Tucker S.P., Watson K.G., Morton C.J. An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med. Chem. Lett. 2012;3:303&#x2013;307. doi: 10.1021/ml2002955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ml2002955</ArticleId><ArticleId IdType="pmc">PMC4025830</ArticleId><ArticleId IdType="pubmed">24900468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gern J.E. How rhinovirus infections cause exacerbations of asthma. Clin. Exp. Allergy. 2015;45:32&#x2013;42. doi: 10.1111/cea.12428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.12428</ArticleId><ArticleId IdType="pubmed">25270551</ArticleId></ArticleIdList></Reference><Reference><Citation>Groarke J.M., Pevear D.C. Attenuated virulence of pleconaril&#x2010;resistant coxsackievirus B3 variants. J. Infect. Dis. 1999;179:1538&#x2013;1541. doi: 10.1086/314758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314758</ArticleId><ArticleId IdType="pubmed">10228078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Herrington D.T., Coats T.L., Kim K., Cooper E.C., Villano S.A., Liu S., Hudson S., Pevear D.C., Collett M., McKinlay M. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 2003;36:1523&#x2013;1532. doi: 10.1086/375069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375069</ArticleId><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Hipskind G.J., Woerner D.H., Eisen G.F., Janssens M., Janssen P.A., Andries K. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 1995;39:290&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162529</ArticleId><ArticleId IdType="pubmed">7726484</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz B.A., Rueckert R.R., Shepard D.A., Dutko F.J., McKinlay M.A., Fancher M., Rossmann M.G., Badger J., Smith T.J. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 1989;63:2476&#x2013;2485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250706</ArticleId><ArticleId IdType="pubmed">2542566</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T., Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev. Med. Virol. 2015;25:102&#x2013;114. doi: 10.1002/rmv.1820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1820</ArticleId><ArticleId IdType="pmc">PMC4407910</ArticleId><ArticleId IdType="pubmed">25471236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick B.D., Mychaleckyj J.C. Polio eradication: inching forward, with safety nets. Lancet Infect. Dis. 2015;15:1244&#x2013;1245. doi: 10.1016/S1473-3099(15)00261-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00261-3</ArticleId><ArticleId IdType="pubmed">26318713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus W., Zimmermann H., Eggers H.J., Nelsen-salz B. vol. 71. 1997. pp. 1697&#x2013;1702. (Rhodanine Resistance and Dependence of Echovirus 12&#xa0;: a Possible Consequence of Capsid Flexibility).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191234</ArticleId><ArticleId IdType="pubmed">8995703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix C., Querol-Aud&#xed; J., Roche M., Franco D., Froeyen M., Guerra P., Terme T., Vanelle P., Verdaguer N., Neyts J., Leyssen P. A novel benzonitrile analogue inhibits rhinovirus replication. J. Antimicrob. Chemother. 2014;69:2723&#x2013;2732. doi: 10.1093/jac/dku200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku200</ArticleId><ArticleId IdType="pubmed">24948704</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Wang J. EV71 vaccine, an invaluable gift for children. Clin. Transl. Immunol. 2014;3:e28. doi: 10.1038/cti.2014.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2014.24</ArticleId><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.-M., Roberts J.A., Moore D., Anderson B., Pallansch M.A., Pevear D.C., Collett M.S., Oberste M.S. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob. Agents Chemother. 2012;56:5568&#x2013;5574. doi: 10.1128/AAC.00539-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00539-12</ArticleId><ArticleId IdType="pmc">PMC3486616</ArticleId><ArticleId IdType="pubmed">22890765</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;nnrot M., Sj&#xf6;roos M., Salminen K., Maaronen M., Hyypi&#xe4; T., Hy&#xf6;ty H. Diagnosis of enterovirus and rhinovirus infections by RT-PCR and time-resolved fluorometry with lanthanide chelate labeled probes. J. Med. Virol. 1999;59:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">10502272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallia P., Message S.D., Gielen V., Contoli M., Gray K., Kebadze T., Aniscenko J., Laza-Stanca V., Edwards M.R., Slater L., Papi A., Stanciu L.A., Kon O.M., Johnson M., Johnston S.L. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 2011;183:734&#x2013;742. doi: 10.1164/rccm.201006-0833OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201006-0833OC</ArticleId><ArticleId IdType="pmc">PMC3081284</ArticleId><ArticleId IdType="pubmed">20889904</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz J. Vapendavir significantly improves upper respiratory symptoms of naturally acquired rhinovirus infection in asthmatic adults: results of a phase 2 clinical trial. Eur. Respir. J. 2013;42</Citation></Reference><Reference><Citation>McGoldrick A., Macadam A.J., Dunn G., Rowe A., Burlison J., Minor P.D., Meredith J., Evans D.J., Almond J.W. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J. Virol. 1995;69:7601&#x2013;7605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189699</ArticleId><ArticleId IdType="pubmed">7494267</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay M.A., Miralles J.V., Brisson C.J., Pancic F. Prevention of human poliovirus-induced paralysis and death in mice by the novel antiviral agent arildone. Antimicrob. Agents Chemother. 1982;22:1022&#x2013;1025. doi: 10.1128/aac.22.6.1022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.22.6.1022</ArticleId><ArticleId IdType="pmc">PMC185714</ArticleId><ArticleId IdType="pubmed">7159068</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Asturias E.J., Hixon A.M., Van Leer-Buter C., Niesters H.G.M., Tyler K.L., Abzug M.J., Dominguez S.R. Enterovirus D68 and acute flaccid myelitis&#x2014;evaluating the evidence for causality. Lancet Infect. Dis. 2018;18:e239&#x2013;e247. doi: 10.1016/S1473-3099(18)30094-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30094-X</ArticleId><ArticleId IdType="pmc">PMC6778404</ArticleId><ArticleId IdType="pubmed">29482893</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Schreiner T.L., Van Haren K., Yang M., Glaser C.A., Tyler K.L., Dominguez S.R. Acute flaccid myelitis: a clinical review of US cases 2012-2015. Ann. Neurol. 2016;80:326&#x2013;338. doi: 10.1002/ana.24730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24730</ArticleId><ArticleId IdType="pmc">PMC5098271</ArticleId><ArticleId IdType="pubmed">27422805</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra N., Ng T.F.F., Marine R.L., Jain K., Ng J., Thakkar R., Caciula A., Price A., Garcia J.A., Burns J.C., Thakur K.T., Hetzler K.L., Routh J.A., Konopka-Anstadt J.L., Nix W.A., Tokarz R., Briese T., Oberste M.S., Lipkin W.I. Antibodies to enteroviruses in cerebrospinal fluid of patients with acute flaccid myelitis. mBio. 2019;10:e01903&#x2013;e01919. doi: 10.1128/MBIO.01903-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MBIO.01903-19</ArticleId><ArticleId IdType="pmc">PMC6692520</ArticleId><ArticleId IdType="pubmed">31409689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser A.G., Rueckert R.R. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J. Virol. 1993;67:1246&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237490</ArticleId><ArticleId IdType="pubmed">8382293</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser A.G., Sgro J.Y., Rueckert R.R. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 1994;68:8193&#x2013;8201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237285</ArticleId><ArticleId IdType="pubmed">7966611</ArticleId></ArticleIdList></Reference><Reference><Citation>Passioti M., Maggina P., Megremis S., Papadopoulos N.G. The common cold: potential for future prevention or cure topical collection on rhinosinusitis. Curr. Allergy Asthma Rep. 2014;14:413. doi: 10.1007/s11882-013-0413-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11882-013-0413-5</ArticleId><ArticleId IdType="pmc">PMC7088639</ArticleId><ArticleId IdType="pubmed">24415465</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605&#x2013;1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Hayden F.G., Demenczuk T.M., Barone L.R., McKinlay M.A., Collett M.S. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob. Agents Chemother. 2005;49:4492. doi: 10.1128/AAC.49.11.4492-4499.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.11.4492-4499.2005</ArticleId><ArticleId IdType="pmc">PMC1280128</ArticleId><ArticleId IdType="pubmed">16251287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pincus S.E., Diamond D.C., Emini E.A., Wimmer E. Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. J. Virol. 1986;57:638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC252779</ArticleId><ArticleId IdType="pubmed">3003395</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Now &#x2013; GPEI [WWW Document], n.d. URL http://polioeradication.org/polio-today/polio-now/(accessed 4.2.19)..</Citation></Reference><Reference><Citation>Rhoden E., Liu H.-M., Wang-Chern S., Oberste M.S. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antivir. Res. 2013;98:186&#x2013;191. doi: 10.1016/j.antiviral.2013.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.003</ArticleId><ArticleId IdType="pubmed">23499651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombaut B., Andries K., Boeye A. A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. J. Gen. Virol. 1991;72:2153&#x2013;2157. doi: 10.1099/0022-1317-72-9-2153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-72-9-2153</ArticleId><ArticleId IdType="pubmed">1716654</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard D.A., Heinz B.A., Rueckert R.R. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J. Virol. 1993;67:2245&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240355</ArticleId><ArticleId IdType="pubmed">8383239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Meijer A., Froeyen M., Zhang L., Thibaut H.J., Baggen J., George S., Vernachio J., van Kuppeveld F.J.M., Leyssen P., Hilgenfeld R., Neyts J., Delang L. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob. Agents Chemother. 2015;59:7782&#x2013;7785. doi: 10.1128/AAC.01375-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01375-15</ArticleId><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapparel C., Siegrist F., Petty T.J., Kaiser L. Picornavirus and enterovirus diversity with associated human diseases. Infect. Genet. Evol. 2013;14:282&#x2013;293. doi: 10.1016/J.MEEGID.2012.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MEEGID.2012.10.016</ArticleId><ArticleId IdType="pubmed">23201849</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A., Franco D., Tucker S., Hilgenfeld R., Froeyen M., Leyssen P., Neyts J. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 2014;58:6990&#x2013;6992. doi: 10.1128/AAC.03328-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03328-14</ArticleId><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A., Thibaut H.J., Spieser S.A.H., De Palma A., Koukni M., Rhoden E., Oberste S., P&#xfc;rstinger G., Volny-Luraghi A., Martin J., Marchand A., Chaltin P., Neyts J., Leyssen P. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. Antivir. Res. 2014;110:1&#x2013;9. doi: 10.1016/j.antiviral.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.07.003</ArticleId><ArticleId IdType="pubmed">25043639</ArticleId></ArticleIdList></Reference><Reference><Citation>Uprety P., Curtis D., Elkan M., Fink J., Rajagopalan R., Zhao C., Bittinger K., Mitchell S., Ulloa E.R., Hopkins S., Graf E.H. Association of enterovirus D68 with acute flaccid myelitis. Emerg. Infect. Dis. 2019;25:1676&#x2013;1682. doi: 10.3201/eid2509.190468. Philadelphia, Pennsylvania, USA, 2009&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2509.190468</ArticleId><ArticleId IdType="pmc">PMC6711208</ArticleId><ArticleId IdType="pubmed">31407660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">7630882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>